Gallbladder cancer (GBC) is a rare biliary tract malignancy seen in most developed countries, widespread with extensive geographic and ethnic variance \[[@b1-jptm-2019-11-13]\]. Annually, GBC affects less than two out of 100,000 individuals but is more commonly observed in India, Chile, Japan, and Korea than in Western countries \[[@b2-jptm-2019-11-13],[@b3-jptm-2019-11-13]\]. Most patients present with an advanced stage at diagnosis and the 5-year survival rate is \< 10% \[[@b4-jptm-2019-11-13]\]. In Korea, the overall incidence of GBC from 2009 to 2013 was 2.96 of 100,000 people among males and 2.79 of 100,000 people among females \[[@b5-jptm-2019-11-13]\]. The 5-year survival rate is 30% and the median survival is 10.7 months \[[@b6-jptm-2019-11-13]\]. Ulsan, where the hospital in this study is located, showed the highest incidence during 2009 to 2013 (4.31/100,000 in men and 4.09/100,000 in women) as compared with the national incidence \[[@b5-jptm-2019-11-13],[@b6-jptm-2019-11-13]\].

In recent years, research on various tumor entities has increasingly focused on immunomodulatory drugs than directly cytotoxic cancer therapies. Genomic sequencing studies have identified a host of genetic aberrations that are potentially targetable in GBC \[[@b7-jptm-2019-11-13],[@b8-jptm-2019-11-13]\]. In particular, the immunomodulatory therapy approach targeting the interaction between programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become increasingly significant. The aberrant expression of PD-L1 allows for tumor cells to escape the host immune system and continue to proliferate. Previous research has demonstrated the association of PD-L1 with tumor aggressiveness and poor prognosis in gastric, esophageal, and hepatocellular carcinoma as well as colonic and lung cancers \[[@b9-jptm-2019-11-13],[@b10-jptm-2019-11-13]\]. It is expected that the therapeutic agents known as immune checkpoint inhibitors will be a key emerging strategy in treating the subgroup of advanced GBC.

Throughout the published literature, scant information is available on the use of PD-L1 as a prognostic marker in GBC. Existing research by Neyaz et al. \[[@b11-jptm-2019-11-13]\] and Lin et al. \[[@b12-jptm-2019-11-13]\] has reported inconsistent and contradictory results. Furthermore, although the possibility of immunotherapy has been studied, relevant information in this area is also very limited so far \[[@b13-jptm-2019-11-13],[@b14-jptm-2019-11-13]\]. This study aimed to investigate the expression of PD-L1 and determine the potential association with prognostic impact in GBC. We also reviewed associations with clinicopathological parameters and survival.

MATERIALS AND METHODS
=====================

Specimens and patient selection
-------------------------------

Formalin-fixed, paraffin-embedded (FFPE) primary GBC tissues were derived from 101 patients at Ulsan University Hospital (UUH) between January 2013 and December 2018. Clinical data were recorded from the UUH electronic medical records, including age, sex, size, location, risk factors (e.g., gallstone, cholecystitis, diabetes mellitus, hypertension), margin of tumor resection, histologic grade, TNM stage, lymph node involvement, lymphovascular invasion or perineural invasion by tumor, adjuvant chemotherapy, and follow-up time in months. Follow-up was completed on April 8, 2019. Overall survival (OS) was the interval either between the initial diagnosis and death or between the initial diagnosis and the last observation among surviving patients, respectively. Progression-free survival (PFS) was the interval between the initial diagnosis and progressive changes in the typical imaging appearance on computed tomography and/or magnetic resonance imaging. No patient underwent chemotherapy before surgery. The pathologic diagnosis was confirmed according to the eighth edition of the American Joint Committee on Cancer staging system \[[@b15-jptm-2019-11-13]\] and the World Health Organization classification systems.

Automated immunohistochemistry
------------------------------

A representative paraffin block from each specimen was chosen for immunohistochemical analysis. We immunohistochemically analyzed PD-L1 expression on 3- to 5-μm tissue sections of FFPE specimens. The primary PD-L1 antibody (rabbit monoclonal antibody clone SP263; Roche Holding AG, Basel, Switzerland) was used in all cases in a concentration of approximately 1.61 μg/mL. A negative control for all cases was also developed using the same antibody to control for potential false-positive staining. Placental tissues served as positive controls. Immunohistochemistry assays were performed on a VENTANA BenchMark ULTRA instrument (Roche Holding AG) according to the manufacturer's instructions.

Evaluation of immunohistochemistry
----------------------------------

The PD-L1 expression proportion score was assessed as the percentage of positive membranous expression on tumor cells, whereas cytoplasmic expression was regarded as negative. Tumor cells with any membranous staining intensity were judged to be positive. Various PD-L1 antibodies and cutoff levels were used in different studies. We assessed PD-L1 expression using the cutoff levels of 1%, 10%, and 50% ([Fig. 1](#f1-jptm-2019-11-13){ref-type="fig"}).

Statistical analysis
--------------------

SPSS ver. 24.0 (IBM Corp., Armonk, NY, USA) was used to conduct statistical analyses. To determine the association between two or more variables and PD-L1 expression, Pearson's chi-square test or Fisher exact test where appropriate were applied, with statistical significance at p \< .05. The univariable analysis of OS and PFS was completed using the Kaplan-Meier method and log-rank test.

Ethics statement
----------------

This study was approved by the institutional review board (IRB) of UUH, who granted a waiver of the need for informed consent (IRB No. 2019-08-017). This study was performed in accordance with the principles of the Declaration of Helsinki.

RESULTS
=======

Clinicopathological characteristics
-----------------------------------

The study group included 101 primary GBC cases, with a female predominance (56.4%). The mean age of the included patients was 68.0 years (range, 40 to 90 years) and 97 patients (96.0%) were aged older than 45 years. Fifty-two patients (51.5%) were diagnosed via simple cholecystectomy specimens and 10 of these underwent further surgery after diagnosis. Risk factors included gallstone (28.7%), cholecystitis (91.0%), hypertension (28.7%), and diabetes (32.7%). The majority of cases showed adenocarcinoma not otherwise specified (n = 82, 81.2%), and the most common type was well-differentiated (n = 45, 44.6%). Although subtype-specific components accompanying adenocarcinoma were present, no cases were diagnosed as either undifferentiated carcinoma, squamous cell carcinoma, adenosquamous cell carcinoma, or neuroendocrine carcinoma. This cohort included mostly patients with early stages of disease; 84 patients (83.2%) presented with pT1 or pT2 category. Among 72 patients eligible for the evaluation of pathologic stage status, 37 (51.4%) presented with stage I or stage II disease. The clinicopathological characteristics of our GBC patients are shown in [Table 1](#t1-jptm-2019-11-13){ref-type="table"}.

Correlation of clinicopathological parameters with PD-L1 expression
-------------------------------------------------------------------

PD-L1 expression in tumor cells was observed in 19 patients (18.8%) with a cutoff level of 1%, 14 patients (13.8%) with a cutoff level of 10%, and eight patients (7.9%) with a cutoff level of 50%. The finding of any positive PD-L1 expression was significantly correlated with poorer and other differentiation (1% cutoff: p = .001; 10% cutoff: p \< .001; 50% cutoff: p \< .001) and the presence of lymphovascular invasion (1% cutoff, p = .015; 10% cutoff, p = .001; 50% cutoff, p = .005). Positive PD-L1 expression with cutoff levels of 10% and 50% was associated with the presence of perineural invasion (10% cutoff, p = .032; 50% cutoff, p = .023), higher T category (10% cutoff, p = .012; 50% cutoff, p = .026), and higher pathologic stage (10% cutoff, p = .045; 50% cutoff, p = .010). In addition, positive PD-L1 expression with 1% and 10% cutoff levels was correlated with larger tumor size (1% cutoff, p = .040; 10% cutoff, p = .007). No significant differences were observed with regard to sex; age; tumor location; margin of tumor resection; adjuvant chemotherapy; or primary risk factors for GBC such as gallstones, cholecystitis, diabetes, and hypertension. The associations between PD-L1 expression in tumor cells and clinicopathological characteristics of GBC patients are shown in [Table 2](#t2-jptm-2019-11-13){ref-type="table"}.

Survival analysis
-----------------

At the time of analysis, the median OS was 14 months (range, 0 to 71 months). Thirty-three patients (32.6%) died during the follow-up period. Meanwhile, a total of 24 patients showed disease progression, and 19 of these patients died. Survival analysis using Kaplan-Meier analysis was performed to evaluate the prognostic impact of PD-L1 expression and other parameters. OS was significantly associated with histologic grade (p = .003), T category (p \< .001), N category (p \< .001), pathologic stage (p \< .001), lymphovascular invasion (p \< .001), perineural invasion (p \< .001), growth pattern (p = .019), and resection margin (p = .006). Worse mean survival was observed in histologic grade progressing from well-differentiated to poorly differentiated, undifferentiated, or other. The patients with higher T categories, nodal metastasis, higher pathologic stages, presence of lymphovascular invasion, and presence of perineural invasion showed poorer OS, whereas those with a polypoid growth pattern and complete resection showed better OS. These parameters were more significantly associated with PFS. Significant differences in both OS and PFS according to PD-L1 expression were seen only at the 50% cutoff statistically (1% cutoff: p = .14; 10% cutoff: p =.259; 50% cutoff: p = .049 for OS and 1% cutoff: p = .095; 10% cutoff: p = .178; 50% cutoff: p = .028 for PFS) ([Fig. 2](#f2-jptm-2019-11-13){ref-type="fig"}). We observed a high expression of PD-L1 correlated with poor prognostic significance of both survival types, especially PFS. Old age (≥ 68 years) was correlated with poor OS and larger tumor size (≥ 2.7 cm) was correlated with poor PFS, respectively. No significant associations with sex, histologic type, adjuvant chemotherapy, gallstone status, cholecystitis, diabetes, or hypertension were evident. Correlations between OS or PFS and clinicopathological parameters are shown in [Table 3](#t3-jptm-2019-11-13){ref-type="table"}.

DISCUSSION
==========

Immune checkpoint inhibitors targeting the PD-1--PD-L1 pathway have exhibited potent efficacy in some cancers such as triple-negative breast cancer, renal cell carcinoma, and non-small cell lung cancer \[[@b16-jptm-2019-11-13]-[@b20-jptm-2019-11-13]\]. Clinical benefits were strongly correlated with high PD-L1 expression and certain drugs have been approved for use in conjunction \[[@b20-jptm-2019-11-13],[@b21-jptm-2019-11-13]\]. While PD-L1 expression significantly correlates with poor prognosis in gastric cancer, hepatocellular carcinoma, and esophageal cancer, both better and worse results have been observed in lung cancer, colorectal cancer, and melanoma \[[@b22-jptm-2019-11-13]\]. PD-L1 expression has been suggested as an important prognostic factor, but few studies have evaluated the expression levels of PD-L1 in GBC patients and there are no consistent results regarding its value as a predictor.

Various studies suggest that PD-L1 expression is associated with poor prognostic factors or survival in different tumor types. These studies observed that tumors with poor differentiation, vascular invasion, nodal metastasis, higher stage, adenocarcinoma histology, and lower survival rate were correlated with higher PD-L1 expression. [Table 4](#t4-jptm-2019-11-13){ref-type="table"} summarizes recent studies covering the prognostic value of PD-L1 \[[@b11-jptm-2019-11-13],[@b12-jptm-2019-11-13],[@b23-jptm-2019-11-13]-[@b32-jptm-2019-11-13]\].

In patients with advanced cholangiocarcinoma or gallbladder adenocarcinoma, results from phase I KEYNOTE-028 and phase II KEYNOTE-158 research indicated that pembrolizumab, a humanized monoclonal antibody against PD-1, constitutes a possible treatment option regardless of PD-L1 expression \[[@b14-jptm-2019-11-13]\]. The PD-L1 antibody (22C3) and a 1% cutoff level were used in these trials. Elsewhere, Ha et al. \[[@b33-jptm-2019-11-13]\] found a high level of soluble PD-L1 in the serum represents a negative prognostic factor in advanced cholangiocarcinoma and GBC patients who received palliative chemotherapy. Recently, two other studies evaluated the predictive value of PD-L1 expression using immunohistochemistry in GBC tissues. Neyaz et al. \[[@b11-jptm-2019-11-13]\] examined the relationship between PD-L1 expression in tumor cells and tumor-infiltrating lymphocytes (TILs) at cutoff levels of 1%, 10%, and 50% and clinicopathological characteristics or OS. Their study ultimately showed significant correlations existed in terms of histologic type, histologic grade, TIL density, and stage of disease at all cutoff levels but did not find any significant correlations in conjunction with OS. Lin et al. \[[@b12-jptm-2019-11-13]\] evaluated the expression of PD-L1, PD-L2, and the density of CD8^+^ TIL in association with OS, PFS, and risk factors in gallbladder adenocarcinoma by analyzing PD-L1 expression at a 5% cutoff level and performing four subgroup analyses according to PD-L1 expression and CD8^+^ TILs. According to the results, there were no correlations observed with PD-L1 expression in tumor cells alone except for regarding CD8^+^ TIL density and worse OS. Instead, the study demonstrated the coevaluation of CD8 TIL and PD-L1 had the significant prognostic value, and patients with high TILs and/or PD-L1 positivity had the worst PFS and OS.

Based on the above studies, PD-L1 expression in tumor cells as a predictive marker is controversial in GBC. In this study, we evaluated the expression of PD-L1 in 101 GBC cases and investigated the relationship between PD-L1 expression and various clinicopathological parameters or survival. A standard positive cutoff level or biomarker for PD-L1 has not been established \[[@b34-jptm-2019-11-13]-[@b36-jptm-2019-11-13]\]. Different antibodies (e.g., SP263, SP142, 22C3, 22-8, and E1L3N clones) and cutoff levels (e.g., 1%, 5%, 25%, and 50%) are used in various studies; we used the monoclonal antibody SP263 and the 1%, 10%, and 50% cutoff levels in our investigation. Our study showed a strong positive correlation in poor histologic grade and lymphovascular invasion at any cutoff level of PD-L1 expression. Also, other unfavorable parameters such as perineural invasion, higher T category, and higher pathologic stage of disease showed a significant correlation with PD-L1 expression at the 10% and 50% cutoff levels. Our final aim was to evaluate the prognostic impact of the clinicopathological parameters in survival. In this study, the association between PD-L1 expression at the 50% cutoff level and OS or PFS achieved statistical significance. Other parameters including the presence of lymphovascular invasion and perineural invasion; incomplete resection; higher histologic grade; higher T category, N category, and pathologic stage; and nonpolypoid growth pattern were also significantly associated with poor OS and PFS.

In summary, although opposite results have been reported regarding the use of PD-L1 expression as a predictive parameter in GBC, our results supported the negative clinical impact of PD-L1 expression as described by Lin et al. \[[@b12-jptm-2019-11-13]\]. We found that GBC cases with high PD-L1 expression were significantly associated with poor clinicopathological parameters and survival at the 50% cutoff level. Interestingly, although a significant association with PD-L1 expression was found in the two studies using E1L3N and SP263, SP263 did not display any such significance in the previous study by Neyaz et al. \[[@b11-jptm-2019-11-13]\]. We have to consider the following reasons for discrepancies in PD-L1 expression: dissimilar cutoff levels and anti-PD-L1 antibodies, heterogeneity of tumor, interobserver and intra-observer variability, and the influence of relationships with other indicators such as PD-L1 expression in TILs. Future research with larger study populations focused on elucidating detailed evaluation criteria and identifying the benefit of PD-L1--inhibiting immunomodulating therapies should be conducted.
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![Programmed death-ligand 1 (PD-L1) expression in the tumor cells of gallbladder cancer (GBC). (A) ≥ 50% positive staining of PDL1 in tumor cells. (B) 10% to 49% positive staining of PD-L1 in tumor cells. (C) 1% to 9% staining of PD-L1 in tumor cells. (D) Positive staining of PD-L1 in tumor cells of lymphovascular invasion. (E) Positive staining of PD-L1 in tumor cells of perineural invasion.](jptm-2019-11-13f1){#f1-jptm-2019-11-13}

![Kaplan-Meier plots for overall survival or progression-free survival of gallbladder cancer according to programmed death-ligand 1 (PD-L1) expression (A, 1% cutoff; B, 10% cutoff; C, 50% cutoff; D, 1% cutoff; E, 10% cutoff; F, 50% cutoff).](jptm-2019-11-13f2){#f2-jptm-2019-11-13}

###### 

Clinicopathological characteristics in gallbladder cancer patients

  Clinicopathological variable                                                 No. (%)
  ---------------------------------------------------------------------------- ----------------
  Age, mean (range, yr)                                                        68.0 (40--90)
  Sex                                                                          
   Male                                                                        44 (43.6)
   Female                                                                      57 (56.4)
  Histological type                                                            
   Adenocarcinoma NOS                                                          82 (81.2)
   MANEC                                                                       3 (3.0)
   ICPN with associated invasive carcinoma                                     5 (5.0)
   Adenocarcinoma with undifferentiated carcinoma                              3 (3.0)
   Adenocarcinoma with squamous differentiation                                3 (3.0)
   Adenocarcinoma with sarcomatoid differentiation and sarcomatoid carcinoma   2 (2.0)
   Adenocarcinoma with signet cell component and signet ring cell carcinoma    2 (2.0)
   Mucinous carcinoma                                                          1 (1.0)
  Histologic grade                                                             
   Well differentiated                                                         45 (44.6)
   Moderately differentiated                                                   34 (33.7)
   Poorly differentiated                                                       18 (17.8)
   Undifferentiated                                                            1 (1.0)
   Others (SRC, MUC, SARC)                                                     3 (3.0)
  T category                                                                   
   pT1a                                                                        15 (14.9)
   PT1b                                                                        14 (13.9)
   pT2a                                                                        47 (46.5)
   pT2b                                                                        8 (7.9)
   pT3                                                                         15 (14.9)
   pT4                                                                         2 (2.0)
  N category                                                                   
   Nx                                                                          31 (30.7)
   N0                                                                          37 (36.6)
   N1                                                                          28 (27.7)
   N2                                                                          5 (5.0)
  M category                                                                   
   M0                                                                          98 (97.0)
   M1                                                                          3 (3.0)
  Pathologic stage (total=72)                                                  
   I                                                                           18 (25.0)
   IIA                                                                         16 (22.2)
   IIB                                                                         3 (4.2)
   IIIA                                                                        2 (2.8)
   IIIB                                                                        26 (36.1)
   IVA                                                                         1 (1.4)
   IVB                                                                         6 (8.3)
  Operation                                                                    
   Simple cholecystectomy                                                      43 (42.6)
   Radical cholecystectomy                                                     55 (54.4)
   Pylorus resecting pancreatoduodenectomy with hepatectomy                    2 (2.0)
   Pylorus preserving pancreatoduodenectomy with hepatectomy                   1 (1.0)
  Complete resection                                                           
   Yes                                                                         92 (91.1)
   No                                                                          19 (9.9)
  Adjuvant chemotherapy                                                        
   Not received                                                                71 (70.3)
   Received                                                                    30 (29.7)
  Gallstone                                                                    
   No                                                                          72 (71.3)
   Yes                                                                         29 (28.7)
  Cholecystitis                                                                
   No                                                                          9 (9.0)
   Yes                                                                         92 (91.0)
  Hypertension                                                                 
   No                                                                          72 (71.3)
   Yes                                                                         29 (28.7)
  Diabetes                                                                     
   No                                                                          68 (67.3)
   Yes                                                                         33 (32.7)
  Tumor location                                                               
   Fundus                                                                      36 (35.6)
   Body                                                                        40 (39.6)
   Neck, cystic duct                                                           14 (13.9)
   More than 2 portions                                                        11 (10.9)
  Size, median (range, cm)                                                     2.7 (0.1--6.9)
  Growth pattern                                                               
   Polypoid                                                                    53 (52.5)
   Nonpolypoid, ulcerative                                                     48 (47.5)
  Lymphovascular invasion                                                      
   Absent                                                                      62 (61.4)
   Present                                                                     39 (38.6)
  Perineural invasion                                                          
   Absent                                                                      65 (64.4)
   Present                                                                     36 (35.6)
  PD-L1 expression (%)                                                         
   \< 1                                                                        82 (81.2)
   1--9                                                                        5 (5.0)
   10--49                                                                      6 (5.9)
   ≥ 50                                                                        8 (7.9)

Values are presented as number (%).

NOS, not otherwise specified; MANEC, mixed adenoneuroendocrine carcinoma; ICPN, intracholecystic papillary neoplasm; SRC, signet ring cell carcinoma; MUC, mucinous carcinoma; SARC, sarcomatoid carcinoma; PDL1, programmed death-ligand 1.

###### 

Correlation of clinicopathological parameters with PD-L1 expression in GBC

  Clinicopathological parameter                                  PD-L1       p-value     PD-L1                                                   p-value     PD-L1       p-value                                                                           
  -------------------------------------------------------------- ----------- ----------- ------------------------------------------------------- ----------- ----------- ---------------------------------------------------------- ----------- ---------- ----------------------------------------------------------
  Sex                                                                                    .887                                                                            .270                                                                              \> .99^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   Male                                                          36 (43.9)   8 (42.1)                                                            36 (41.4)   8 (57.1)                                                               41 (44.1)   3 (37.5)   
   Female                                                        46 (56.1)   11 (57.9)                                                           51 (58.6)   6 (42.9)                                                               52 (55.9)   5 (62.5)   
  Age (yr)                                                                               .259                                                                            .302                                                                              .716^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   \< 68                                                         42 (51.2)   7 (36.8)                                                            44 (50.6)   5 (35.7)                                                               46 (49.5)   3 (37.5)   
   ≥ 68                                                          40 (48.8)   12 (63.2)                                                           43 (49.4)   9 (64.3)                                                               47 (50.5)   5 (62.5)   
  Histologic type                                                                        .132^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                           .004^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                             .306^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   Adenocarcinoma NOS, ICPN with associated invasive carcinoma   73 (89.0)   14 (73.7)                                                           79 (90.8)   8 (57.1)                                                               81 (87.1)   6 (75.0)   
   Adenocarcinoma with other component, others                   9 (11.0)    5 (26.3)                                                            8 (9.2)     6 (42.9)                                                               12 (12.9)   2 (25.0)   
  Histologic grade                                                                       .001                                                                            \< .001^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                          \< .001^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   Well differentiated                                           42 (51.2)   3 (15.8)                                                            44 (50.6)   1 (7.1)                                                                45 (48.4)   0          
   Moderately differentiated                                     28 (34.1)   6 (31.6)                                                            31 (35.6)   3 (21.4)                                                               33 (35.5)   1 (12.5)   
   Poorly differentiated, undifferentiated, others               12 (14.6)   10 (52.6)                                                           12 (13.8)   10 (71.4)                                                              15 (16.1)   7 (87.5)   
  T category                                                                                                                                                                                                                                               
   pT1 + pT2                                                     70 (85.4)   14 (73.7)   .304^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^   76 (87.4)   8 (57.1)    .012^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^      80 (86.0)   4 (50.0)   .026^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   pT3 + pT4                                                     12 (14.6)   5 (26.3)                                                            11 (12.6)   6 (42.9)                                                               13 (14.0)   4 (50.0)   
  N category                                                                             .260                                                                            .137                                                                              .093^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   N0                                                            31 (56.4)   6 (40.0)                                                            33 (56.9)   4 (33.3)                                                               36 (56.3)   1 (16.7)   
   N1 + N2                                                       24 (43.6)   9 (60.0)                                                            25 (43.1)   8 (66.7)                                                               28 (43.8)   5 (83.3)   
  Pathologic stage                                                                       .116                                                                            .045                                                                              .010^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
  I + II                                                         32 (56.1)   5 (33.3)                                                            34 (56.7)   3 (25.0)                                                               37 (56.1)   0          
  III + IV                                                       25 (43.9)   10 (66.7)                                                           26 (43.3)   9 (75.0)                                                               29 (43.9)   6 (100)    
  Growth pattern                                                                         .315                                                                            .437                                                                              \> .99^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
  Polypoid                                                       45 (54.9)   8 (42.1)                                                            47 (54.0)   6 (42.9)                                                               49 (52.7)   4 (50.0)   
  Nonpolypoid (ulcerative)                                       37 (45.1)   11 (57.9)                                                           40 (46.0)   8 (57.1)                                                               44 (47.3)   4 (50.0)   
  Lymphovascular invasion                                                                .015                                                                            .001                                                                              .005^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   No                                                            55 (67.1)   7 (36.8)                                                            59 (67.8)   3 (21.4)                                                               61 (65.6)   1 (12.5)   
   Yes                                                           27 (32.9)   12 (63.2)                                                           28 (32.2)   11 (78.6)                                                              32 (34.4)   7 (87.5)   
  Perineural invasion                                                                    .086                                                                            .032^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                             .023^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   No                                                            56 (68.3)   9 (47.4)                                                            60 (69.0)   5 (35.7)                                                               63 (67.7)   2 (25.0)   
   Yes                                                           26 (31.7)   10 (52.6)                                                           27 (31.0)   9 (64.3)                                                               30 (32.3)   6 (75.0)   
  Tumor location                                                                         .487^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                           .079^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                             .060^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   Fundus                                                        30 (36.6)   6 (31.6)                                                            31 (35.6)   5 (35.7)                                                               35 (37.6)   1 (12.5)   
   Body                                                          33 (40.2)   7 (36.8)                                                            35 (40.2)   5 (35.7)                                                               36 (38.7)   4 (50.0)   
   Neck, cystic duct                                             12 (14.6)   2 (10.5)                                                            14 (16.1)   0                                                                      14 (15.1)   0          
   More than 2 portions                                          7 (8.5)     4 (21.1)                                                            7 (8.0)     4 (28.6)                                                               8 (8.6)     3 (37.5)   
  Tumor size (cm)                                                                        .040                                                                            .007                                                                              .062^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   \< 2.7                                                        43 (52.4)   5 (26.3)                                                            46 (52.9)   2 (14.3)                                                               47 (50.5)   1 (12.5)   
   ≥ 2.7                                                         39 (47.6)   14 (73.7)                                                           41 (47.1)   12 (85.7)                                                              46 (49.5)   7 (87.5)   
  Complete resection                                                                     .676^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                           \> .99^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                           .539^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   Yes                                                           75 (91.5)   17 (89.5)                                                           79 (90.8)   13 (92.9)                                                              85 (91.4)   7 (87.5)   
   No                                                            7 (8.5)     2 (10.5)                                                            8 (9.2)     1 (7.1)                                                                8 (8.6)     1 (12.5)   
  Adjuvant chemotherapy                                                                  .720                                                                            .344^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                             .233^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   No or refuse                                                  57 (69.5)   14 (73.7)                                                           63 (72.4)   8 (57.1)                                                               67 (72.0)   4 (50.0)   
   Yes                                                           25 (30.5)   5 (26.3)                                                            24 (27.6)   6 (42.9)                                                               26 (28.6)   4 (50.0)   
  Gallstone                                                                              .798                                                                            .339^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                             .433^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   No                                                            58 (70.7)   14 (73.7)                                                           60 (69.0)   12 (85.7)                                                              65 (69.9)   7 (87.5)   
   Yes                                                           24 (29.3)   5 (26.3)                                                            27 (31.0)   2 (14.3)                                                               28 (30.1)   1 (12.5)   
  Cholecystitis                                                                          .228                                                                            .727                                                                              \> .99
   No                                                            21 (91.3)   2 (8.7)                                                             21 (91.3)   2 (8.7)                                                                21 (91.3)   2 (8.7)    
   Yes                                                           61 (78.2)   17 (21.8)                                                           67 (85.9)   11 (14.1)                                                              72 (92.3)   6 (7.7)    
  Diabetes                                                                               .512                                                                            .137^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^                             .268^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   No                                                            54 (65.9)   14 (73.7)                                                           56 (64.4)   12 (85.7)                                                              61 (65.6)   7 (87.5)   
   Yes                                                           28 (34.1)   5 (26.3)                                                            31 (35.6)   2 (14.3)                                                               32 (34.4)   1 (12.5)   
  Hypertension                                                                           .729                                                                            .346                                                                              .255^[a](#tfn1-jptm-2019-11-13){ref-type="table-fn"}^
   No                                                            51 (62.2)   11 (57.9)                                                           55 (63.2)   7 (50.0)                                                               59 (63.4)   3 (37.5)   
   Yes                                                           31 (37.8)   8 (42.1)                                                            32 (36.8)   7 (50.0)                                                               34 (36.6)   5 (62.5)   

Values are presented as number (%).

Statistical analysis method: Pearson chi-square test.

PD-L1, programmed death-ligand 1; GBC, gallbladder cancer; NOS, not otherwise specified; ICPN, intracholecystic papillary neoplasm; Others, mixed adenoneuroendocrine carcinoma, signet ring cell carcinoma, mucinous carcinoma, sarcomatoid carcinoma.

Fisher exact test.

###### 

Correlation of clinicopathological parameters with OS or PFS in GBC

  Clinicopathological parameter                                  OS (mo)        p-value   PFS (mo)       p-value
  -------------------------------------------------------------- -------------- --------- -------------- ---------
  Sex                                                                           .632                     .694
   Male                                                          50.61 ± 4.57             49.90 ± 4.82   
   Female                                                        45.90 ± 3.78             45.21 ± 3.97   
  Age (yr)                                                                      .044                     .070
   \<68                                                          52.37 ± 3.65             51.07 ± 3.99   
   ≥68                                                           42.52 ± 4.61             41.30 ± 4.85   
  Histologic type                                                               .385                     .349
   Adenocarcinoma NOS, ICPN with associated invasive carcinoma   49.57 ± 3.27             49.04 ± 3.42   
   Adenocarcinoma with other component, others                   38.81 ± 6.30             36.73 ± 6.74   
  Histologic grade                                                              .003                     .002
   Well differentiated                                           59.50 ± 3.62             59.02 ± 3.79   
   Moderately differentiated                                     40.43 ± 4.59             39.81 ± 4.87   
   Poorly differentiated, undifferentiated, others               33.07 ± 5.16             30.12 ± 5.63   
  T category                                                                    \< .001                  \< .001
   pT1 + pT2                                                     53.37 ± 3.17             52.98 ± 3.28   
   pT3 + pT4                                                     25.05 ± 5.41             19.64 ± 6.02   
  N category                                                                    \< .001                  \< .001
   N0                                                            62.85 ± 3.28             62.31 ± 3.46   
   N1 + N2                                                       34.51 ± 5.05             32.62 ± 5.75   
  Pathologic stage                                                              \< .001                  \< .001
   I + II                                                        62.53 ± 3.25             62.43 ± 3.31   
   III + IV                                                      34.86 ± 4.92             33.03 ± 5.54   
  Lymphovascular invasion                                                       \< .001                  \< .001
   No                                                            58.03 ± 3.26             57.79 ± 3.33   
   Yes                                                           31.38 ± 4.34             28.17 ± 4.89   
  Perineural invasion                                                           \< .001                  \< .001
   No                                                            55.46 ± 3.00             55.17 ± 3.10   
   Yes                                                           31.91 ± 5.06             29.65 ± 5.59   
  Tumor location                                                                .050                     .094
   Fundus                                                        42.46 ± 4.07             42.17 ± 4.44   
   Body                                                          48.36 ± 4.42             47.67 ± 4.61   
   Neck, cystic duct                                             57.13 ± 6.88             55.27 ± 7.91   
   More than 2 portions                                          24.73 ± 6.50             24.64 ± 6.82   
  Tumor size (cm)                                                               .058                     .042
   \< 2.7                                                        54.65 ± 4.14             54.16 ± 4.29   
   ≥ 2.7                                                         41.27 ± 3.85             39.84 ± 4.15   
  Growth pattern                                                                .019                     .015
   Polypoid                                                      55.12 ± 3.77             54.68 ± 3.90   
   Nonpolypoid, ulcerative                                       37.52 ± 3.89             35.82 ± 4.35   
  Complete resection                                                            .006                     .005
   Yes                                                           25.63 ± 8.72             22.98 ± 9.38   
   No                                                            50.67 ± 3.12             49.98 ± 3.28   
  Adjuvant chemotherapy                                                         .488                     .322
   No                                                            48.58 ± 3.43             48.08 ± 3.54   
   Yes                                                           45.27 ± 5.46             43.02 ± 6.11   
  Gallstone                                                                     .066                     .095
   No                                                            50.26 ± 3.28             49.54 ± 3.47   
   Yes                                                           38.78 ± 5.63             38.31 ± 5.87   
  Cholecystitis                                                                 .668                     .694
   No                                                            47.70 ± 4.54             47.02 ± 4.85   
   Yes                                                           47.78 ± 3.64             47.45 ± 3.78   
  Diabetes                                                                      .270                     .222
   No                                                            50.89 ± 3.72             50.38 ± 3.90   
   Yes                                                           42.10 ± 4.57             40.50 ± 4.86   
  Hypertension                                                                  .615                     .619
   No                                                            45.93 ± 3.55             44.93 ± 3.78   
   Yes                                                           51.21 ± 4.96             51.02 ± 5.07   
  PD-L1 expression                                                                                       
   PD-L1 \< 1%                                                   50.53 ± 3.29   .144      49.95 ± 3.43   .095
   PD-L1 ≥ 1%                                                    31.35 ± 4.42             28.75 ± 5.17   
   PD-L1 \< 10%                                                  49.80 ± 3.24   .259      49.27 ± 3.38   .178
   PD-L1 ≥ 10%                                                   32.89 ± 5.03             30.31 ± 5.75   
   PD-L1 \< 50%                                                  50.13 ± 3.14   .049      49.48 ± 3.29   .028
   PD-L1 ≥ 50%                                                   27.88 ± 6.69             23.33 ±7.47    

Values are presented as mean ± standard error.

Statistical analysis method: survival analysis by Kaplan-Meier method and log-rank test.

OS, overall survival; PFS, progression-free survival; GBC, gallbladder cancer; NOS, not otherwise specified; ICPN, intracholecystic papillary neoplasm; others, mixed adenoneuroendocrine carcinoma, signet ring cell carcinoma, mucinous carcinoma,sarcomatoid carcinoma; PD-L1, programmed death-ligand 1.

###### 

PD-L1 expression in tumor cells in various tumors

  Disease                           No.                    Detection specimen; detection antibody                                PD-L1 expression cutoff (%)                    Other clinicopathological parameters associated with PD-L1 expression                                                                                                                                                                 Survival with PD-L1 expression                                                                                                                           Study
  --------------------------------- ---------------------- --------------------------------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------
  Gallbladder cancer                174                    FFPE tissue; anti--PD-L1 (clone SP263)                                1, 10, 50                                      Significant positive association with histologic type (squamous cell carcinoma, adenosquamous cell carcinoma, undifferentiated carcinoma), histologic grade (progressed from WD to PD), nuclear grade, stage 3 and 4, TIL (0 to 3+)   OS was not associated with PD-L1 expression                                                                                                              Neyaz et al. \[[@b11-jptm-2019-11-13]\]
  Gallbladder adenocarcinoma        66                     FFPE tissue; anti--PD-L1 (E1L3N)                                      5                                              PD-L1 positive alone was not correlated with any clinicopathological or pathological parameters except for CD8+ TIL density and worse median OS                                                                                       Combination of CD8 high with negative expression of PD-L1 serves as prognostic factor for improved OS and PFS                                            Lin et al. \[[@b12-jptm-2019-11-13]\]
  Gastric adenocarcinoma            240                    FFPE tissue; anti--PD-L1 (E1L3N)                                      10                                             Patients with poor tumor differentiation had a higher positive rate of PD-L1 expression on tumor cells                                                                                                                                Positive PD-L1 expression on TILs had a shorter OS; However, PD-L1 expression on tumor cells was not associated with OS                                  Fang et al. \[[@b23-jptm-2019-11-13]\]
  Gastric cancer                    107                    FFPE tissue; anti--PDL1 (polyclonal antihuman PD-L1/CD274 antibody)   Not applicable                                 Positive rate of PD-L1 expression is much higher in depth of invasion, high differentiation, lymph node metastasis, and higher T category                                                                                             PD-L1--positive gastric cancers were significantly associated with a poor prognosis                                                                      Qing et al. \[[@b24-jptm-2019-11-13]\]
  Esophageal cancer                 41                     Frozen tissue; anti--PD-L1 (MIH1, mouse IgG1)                         10                                             Effect of PD-L1 status was more distinct in the advanced stage of tumor with lymph node metastasis and distinct metastasis                                                                                                            Overall survival of patients with tumors positive for both PD-L1 and PD-L2 was significantly worse than that with tumors negative for both               Ohigashi et al. \[[@b25-jptm-2019-11-13]\]
  Colorectal cancer                 143                    FFPE tissue; anti--PD-L1 (Abcam, ab58810)                             Strong and moderate immunostaining intensity   PD-L1 was significantly associated with cell differentiation status and TNM stage                                                                                                                                                     Positive PD-L1 expression showed a trend shorter survival time; as an independent predictor of prognosis                                                 Shi et al. \[[@b26-jptm-2019-11-13]\]
  Lung adenocarcinoma               163                    FFPE tissue; anti--PD-L1 (Proteintech Group Inc., Chicago, IL, USA)   5                                              PD-L1 had higher positive results in tumors with higher grade differentiation and vascular invasion                                                                                                                                   PD-L1 expression correlated with better RFS                                                                                                              Yang et al. \[[@b27-jptm-2019-11-13]\]
  Lung non-small cell carcinoma     819                    FFPE tissue; anti--PD-L1 (22C3)                                       50                                             Lower PD-L1 positivity correlated with lower stage and squamous cell carcinoma than adenocarcinoma                                                                                                                                    Not assessed                                                                                                                                             Skov et al. \[[@b28-jptm-2019-11-13]\]
  Extrahepatic cholangiocarcinoma   69                     FFPE tissue; anti--PD-L1 (E1L3N)                                      Not applicable                                 Significant correlations of PD-L1 expression with venous invasion and poor differentiation of the tumor were observed                                                                                                                 PD-L1 expression was not correlated with patient OS, but combined high PDL1 expression on tumor cells and low infiltration of CD3+ TILs showed poor OS   Walter D et al. \[[@b29-jptm-2019-11-13]\]
  Hepatocellular carcinoma          240 + additional 125   FFPE tissue; anti--PD-L1 (eBioscience)                                High vs. low                                   PD-L1 expression was an independent prognostic factor for tumor vascular invasion, encapsulation, and TNM stage                                                                                                                       PD-L1--positive (high expression) patients had significantly poorer DFS and OS                                                                           Gao et al. \[[@b30-jptm-2019-11-13]\]
  Hepatocellular carcinoma          448                    FFPE tissue; anti--PD-L1 (E1L3N)                                      1, 5                                           No significant difference in PD-L1 expression was detected                                                                                                                                                                            Survival analysis showed that 5% PD-L1 expression was significantly correlated with improved rates of OS and RFS                                         Chen et al. \[[@b31-jptm-2019-11-13]\]
  Uveal melanoma                    67                     FFPE tissue; anti--PD-L1 (E1L3N)                                      5                                              Significant association of PD-L1 expression to a decreased number of TIL                                                                                                                                                              PD-L1 expression is associated with metastasis-free survival                                                                                             Zoroquiain et al. \[[@b32-jptm-2019-11-13]\]

PD-L1, programmed death-ligand 1; FFPE, formalin-fixed, paraffin-embedded; WD, well-differentiated; PD, poorly differentiated; TIL, tumor-infiltrating lymphocyte; OS, overall survival; PFS, progression-free survival.
